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Abstract
In randomized trials, appropriately adjusting for baseline variables and short-term
outcomes can lead to increased precision and reduced sample size. We examine the
impact of such adjustment in group sequential designs, i.e., designs with preplanned
interim analyses where enrollment may be stopped early for efficacy or futility. We
address the following questions: how much precision gain can be obtained by appropri-
ately adjusting for baseline variables and a short-term outcome? How is this precision
gain impacted by factors such as the proportion of pipeline participants (those who
enrolled but haven’t yet had their primary outcomes measured) and treatment effect
heterogeneity? What is the resulting impact on power and average sample size in a
group sequential design? We derive an asymptotic formula that decomposes the overall
precision gain from adjusting for baseline variables and a short-term outcome into con-
tributions from factors mentioned above, for efficient estimators in the model that only
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assumes randomization and independent censoring. We use our formula to approxi-
mate the precision gain from a targeted minimum loss-based estimator applied to data
from a completed trial of a new surgical intervention for stroke. Our formula implies
that (for an efficient estimator) adjusting for a prognostic baseline variable leads to at
least as much asymptotic precision gain as adjusting for an equally prognostic short-
term outcome. In many cases, such as our stroke trial application, the former leads
to substantially greater precision gains than the latter. In our simulation study, we
show how precision gains from adjustment can be converted into sample size reductions
(even when there is no treatment effect).
Keywords: Short-term outcome; Semiparametric efficiency; Targeted minimum loss-based
estimator
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1 Introduction
Group sequential designs for randomized clinical trials involve interim analyses that may
result in early stopping for efficacy or futility. We consider trial designs where the primary
outcome is measured at a fixed time (called the delay) after enrollment. Prior to observing
the primary outcome, participants may have baseline variables and a short-term outcome
measured. For example, in the MISTIE-II trial (Hanley et al., 2016) for evaluating a surgical
treatment for intracerebral hemorrhage the primary outcome is the modified Rankin Scale
(mRS), which measures degree of disability, 180 days after enrollment. A short-term outcome
is mRS 30 days after enrollment. The baseline (pre-randomization) variables include age and
measures of stroke severity.
Estimators that adjust for baseline variables are used in randomized trials because of
the potential for increased precision and reduced sample size. Pocock et al. (2002), who
surveyed 50 clinical trial reports from major medical journals, found that 36 adjusted for
baseline variables. Adjusting for prognostic baseline variables is recommended by regulators,
e.g., FDA and EMA (1998); EMA (2015); FDA (2019). Also, in order to address missing
outcomes, it may be useful to appropriately adjust for baseline and post-randomization
variables (e.g., short-term outcomes) (National Research Council, 2010; EMA, 2010).
Various methods for adjustment in randomized trials have been developed; see, e.g., Leon
et al. (2003); Davidian et al. (2005); Tsiatis et al. (2008); Rubin and van der Laan (2008);
Moore and van der Laan (2009); Moore et al. (2011). There has also been discussion on
the benefits and limitations of adjustment, compared to the standard, unadjusted estimator
(Yang and Tsiatis, 2001; Freedman, 2008; Lin et al., 2013). Moore et al. (2011) present a
formula for the precision gain from adjusting for baseline variables in single stage trials.
We focus on estimating the average treatment effect for continuous or binary outcomes.
We derive a formula for the asymptotic precision gain (measured by the relative efficiency
compared to the unadjusted estimator) due to adjustment for baseline variables and a short-
term outcome using efficient estimators, that is, estimators that extract the maximum prog-
nostic information from these variables. The formula can be used in trial planning to ap-
proximate the precision gain from adjustment, which can translate to reduced sample size.
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We show, using data of the MISTIE-II trial, how a modified version of these formulas
can be used to approximate the precision gain from using the targeted minimum loss-based
estimator (TMLE) of van der Laan and Gruber (2012) while accounting for model misspec-
ification.
We highlight a few implications of our formula. Holding other factors fixed, larger treat-
ment effect heterogeneity decreases the value added from adjusting for baseline variables of
all participants; however, for the pipeline participants, adjusting for their baseline variables
leads to increased precision only when there is treatment effect heterogeneity. Adjusting for
prognostic baseline variables typically leads to precision gains even if all participants have
their primary outcomes observed. In contrast, adjusting for a prognostic short-term out-
come can only improve precision when there are participants with the short-term outcome
observed but the primary outcome unobserved.
In Section 2, we introduce notation and assumptions. In Section 3, we present our formula
for precision gain. We show how to approximate the precision gain from using a TMLE in
Section 4. In Section 5, we apply our formula to data from the MISTIE-II trial. In Section
6, we conduct simulation studies. Limitations and open problems are discussed in Section 7.
2 Notation and Assumptions
For participant i, let Ai denote the indicator of study arm assignment. We assume Ai is
binary-valued with Ai = 1 for treatment and Ai = 0 for control. Denote by Wi a vector
of baseline variables measured before randomization. All variables must be preplanned in
the trial protocol. Denote by Li a short-term outcome, which is observed at time dL after
enrollment. Though all of our results hold if Li is any prespecified variable measured after
randomization, not necessarily the outcome measured at an earlier time, we focus on the case
of short-term outcomes. Also, for simplicity, we focus on cases with binary Li; the results
can be generalized to multidimensional, continuous Li. Denote by Yi the primary outcome
(continuous or binary-valued), which is observed at time dY after enrollment with dY ≥ dL.
The delays dL and dY are prespecified and are common to all participants. When followed
up completely, participant i contributes full data (Wi,Ai,Li,Yi).
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Let n denote the sample size. We assume that the set of vectors {(Wi,Ai,Li,Yi)}1≤i≤n
are independent and identically distributed draws from the unknown joint distribution P0
on generic data vector (W,A,L,Y ). The following assumption follows from randomization:
Assumption 1. The study arm assignment A is independent of the baseline variables W
and P (A= 1) =P (A= 0) = 1/2.
Results for randomization probabilities other than 1/2 are in Supplementary Material H.5.
Define the average treatment effect as ∆ =E(Y |A= 1)−E(Y |A= 0). The goal is to test
the null hypothesis of no average treatment benefit: H0 : ∆≤ 0 versus H1 : ∆> 0.
We assume that participants are enrolled at a constant rate. Since not all participants
have full data observed at an interim analysis, we introduce indicators CL and CY to denote
that L and Y , respectively, have been observed at or before a given analysis time. For a
participant, CL = 1 if and only if L is observed, and CY = 1 if and only if Y is observed.
These variables get updated at each analysis. We make the following assumptions:
Assumption 2. (Independent Censoring) (CL,CY ) is independent of (W,A,L,Y ).
Assumption 3. (Monotone Censoring) CL≥CY with probability 1.
An example where Assumptions 2 and 3 hold is when administrative censoring is the only
source of missingness and there are no changes over time in the population who are enrolled;
this is what we simulate in Section 6. At any analysis time, each enrolled participant has
one of the following missingness patterns:
(i) (CL,CY ) = (0,0): a pipeline participant with only (W,A) observed;
(ii) (CL,CY ) = (1,0): a pipeline participant with (W,A,L) observed;
(iii) (CL,CY ) = (1,1): a participant with (W,A,L,Y ) observed.
We assume a nonparametric model for the joint distribution of the variables (W,A,L,Y,CL,CY ),
except that we make Assumptions 1-3. The semiparametric efficiency results in the following
sections are with respect to this model.
For a group sequential design with K stages, we consider the asymptotic setting where
the maximum sample size goes to infinity such that at each interim analysis the proportions
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of enrolled participants with final and short-term outcomes observed converge to constants
py and pl, respectively (where these limit proportions may differ by analysis time, but for
conciseness we suppress their dependence on the analysis time). This asymptotic regime cor-
responds to fixing the delay times dL,dY and analysis times, while increasing the enrollment
rate. We only consider analysis times with py > 0.
The unadjusted estimator of ∆ is the difference between the two arms of the sample
mean of the primary outcome Y , using data from all participants with Y observed, i.e.,∑
iAiC
Y
i Yi/
∑
iAiC
Y
i −
∑
i(1−Ai)CYi Yi/
∑
i(1−Ai)CYi .
All estimators of the average treatment effect ∆ that we consider are regular, asymp-
totically linear (RAL), defined, e.g., by Bickel et al. (1993). Any such estimator ∆̂ of ∆ is
asymptotically normal, i.e.,
√
n(∆̂−∆) d→N(0,σ2) as sample size n goes to infinity, where
d→ denotes convergence in distribution; the variance σ2 is called the asymptotic variance
of ∆̂ and is denoted by AVar(∆̂). For example, the asymptotic variance of the unadjusted
estimator is 2{Var(Y |A= 1)+Var(Y |A= 0)}/py at an analysis time where py fraction of the
enrolled participants have their primary outcome observed. The asymptotic relative effi-
ciency (ARE) between two RAL estimators ∆̂1 and ∆̂2 of ∆ is the inverse of the ratio of
their asymptotic variances: ARE(∆̂1,∆̂2) = AVar(∆̂2)/AVar(∆̂1).
For any random vector X and a∈{0,1}, let Ea(Y |X) and Vara(Y |X) denote E(Y |
X,A= a) and Var(Y |X,A= a), respectively. For example, E1(Y |W ) =E(Y |W,A= 1), and
E1(Y ) =E(Y |A= 1). When no subscript is used on E or Var, these refer to expectation
and variance, respectively, under the population distribution of the corresponding variables.
3 Best Possible Precision Gain
3.1 Formula for Precision Gain
The following result gives the best possible asymptotic variance that can be achieved by a
RAL estimator of the average treatment effect ∆, in terms of the proportions pl,py of enrolled
participants with L and Y observed, respectively, at a given analysis time:
Lemma 1. Suppose Assumptions 1, 2, and 3 hold. The asymptotic variance of any RAL
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estimator of ∆ is at least
Var{E1(Y |W )−E0(Y |W )}+
∑
a∈{0,1}
2
pl
Vara{Ea(Y |L,W )−Ea(Y |W )}
+
∑
a∈{0,1}
2
py
Vara{Y −Ea(Y |L,W )}. (1)
Lemma 1 is a consequence of the efficient influence function of ∆ in our semiparametric
model that only makes the assumptions in Section 2. This efficient influence function is
given in Section H.5 of the Supplementary Material, and follows from Robins and Rotnitzky
(1992); Scharfstein et al. (1999); van der Laan and Robins (2003). The TMLE estimator of
van der Laan and Gruber (2012), which will be discussed in Section 4, achieves this variance
lower bound when all working models are correct. When certain working models for this
estimator are misspecified, one can approximate the corresponding ARE by substituting
regression model fits for conditional expectations in (1); see Section 4.2.
The first term in (1) characterizes the variance in the conditional treatment effect across
different levels of W . We define the treatment effect heterogeneity, denoted by γ, by dividing
the variance of the conditional treatment effect by the sum of variances of Y in each arm:
γ=
Var{E1(Y |W )−E0(Y |W )}∑
a∈{0,1}Vara(Y )
. (2)
The treatment effect heterogeneity γ is invariant to linear transformations of Y , and is
nonnegative. When γ= 0 there is no treatment effect heterogeneity, i.e., the conditional
treatment effect E1(Y |W )−E0(Y |W ) = ∆ with probability 1.
For each arm a∈{0,1}, the variance of Y given A= a can be decomposed as follows:
Vara(Y ) = Vara{Y −Ea(Y |L,W )}+Vara{Ea(Y |L,W )−Ea(Y |W )}+Var{Ea(Y |W )},
(3)
as proved in Section H.2 in the Supplementary Material. The last term in the display above
motivates the following definition of the proportion of the variance in Y explained by W
(summed across arms):
R2W =
∑
a∈{0,1}Var{Ea(Y |W )}∑
a∈{0,1}Vara(Y )
= 1−
∑
a∈{0,1}Vara{Y −Ea(Y |W )}∑
a∈{0,1}Vara(Y )
. (4)
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Similarly, the middle term in (3) motivates the following definition of the proportion of
additional variance in Y explained by L after accounting for W (summed across arms):
R2L|W =
∑
a∈{0,1}Vara{Ea(Y |L,W )−Ea(Y |W )}∑
a∈{0,1}Vara(Y )
. (5)
A RAL estimator of ∆ is efficient (at a given data generating distribution) if it achieves
the asymptotic variance lower bound (1) in the semiparametric model.
Theorem 2. Suppose Assumptions 1, 2, and 3 hold. Consider any analysis time. The ARE
between any efficient RAL estimator of ∆ and the unadjusted estimator is
ARE =
1
1+(py/2)γ−R2W −(1−py/pl)R2L|W
. (6)
The denominator of the right side of the above display never exceeds 1, which follows since
γ≤ 2R2W by the Cauchy-Schwarz inequality.
3.2 Impact of Baseline Variables on Precision Gain
In order to isolate the impact of baseline variables W on the ARE (6), we consider the
case where there is no impact of L, i.e., when R2L|W = 0. This is the case, for example,
when L is independent of Y given A and W . Then the ARE from adjusting for baseline
variables W depends on three factors: the proportion of variance in Y explained by W
(R2W ), the proportion of participants with Y observed among those enrolled (py), and the
treatment effect heterogeneity (γ). We plot in Figure 1 the ARE versus py, considering
different combinations of R2W and γ.
A summary of what is happening in Figure 1 is that with py = 1 and R
2
W fixed, greater
treatment effect heterogeneity (γ) lessens the precision gain from prognostic baseline vari-
ables. However, with fixed R2W > 0 and γ > 0, some precision gain is restored as we decrease
py from 1 to 0 (i.e., as we move from right to left along any line with γ > 0 in Figure 1).
We describe the intuition for these phenomena below. The key idea is that precision gains
result from adjusting for chance imbalances in W both (i) between study arms among the
participants with Y observed, and (ii) between the full sample and the subset with Y ob-
served. Whether the adjustments in (i) and (ii) lead to precision gains or not is determined
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Figure 1: Asymptotic relative efficiency between an efficient estimator and the unadjusted
estimator for estimating ∆, when only the baseline variable W is prognostic (R2L|W = 0 in all
curves).
9
by the treatment effect heterogeneity γ, which influences whether the estimated means in
each arm are adjusted in opposite directions (leading to variance reduction) or in the same
direction (leading to cancellation and no impact). This is analogous to constructive versus
destructive interference between waves, which can lead to cancellation or amplification as
the waves come together.
To give intuition for the phenomena in Figure 1, for the remainder of this subsection we
fix R2W and consider the simple case of a single, binary-valued W representing being less than
65 years old at baseline, and primary outcome Y being the indicator of having mRS at most 3
(a good outcome) at 180 days. We focus on the stratum W = 1 and assume that the under 65
subset of the study population would have better outcomes on average than the overall study
population if all were assigned to the control arm, i.e., E(Y |A= 0,W = 1)−E(Y |A= 0)> 0.
We next consider py = 1 and the opposite extremes of no treatment effect heterogeneity
(where efficiency gains from adjusting for W are maximal) and maximum treatment effect
heterogeneity (where there are no efficiency gains from adjusting for W ).
First, consider the case of py = 1 and no treatment effect heterogeneity (γ= 0), i.e.,
E(Y |A= 1,W )−E(Y |A= 0,W ) equals the constant E(Y |A= 1)−E(Y |A= 0) = ∆. Com-
bining this with the assumption above that those under 65 have better outcomes on av-
erage than the overall study population under assignment to the control arm (E(Y |A=
0,W = 1)−E(Y |A= 0)> 0), it follows that those under 65 also have better outcomes on
average than the overall study population under assignment to the treatment arm, i.e.,
E(Y |A= 1,W = 1)−E(Y |A= 1) =E(Y |A= 0,W = 1)−E(Y |A= 0). If by chance there are
proportionally more under 65 participants assigned to the treatment arm than the control
arm, then the unadjusted estimator of the mean outcome in the treatment (control) arm
is biased upward (downward) conditional on the chance imbalance (Jiang et al., 2019). An
efficient estimator adjusts for this by decreasing the unadjusted estimate of E(Y |A= 1) and
by increasing the unadjusted estimate of E(Y |A= 0); the net impact is to decrease the esti-
mate of ∆. Alternatively, if by chance there are proportionally fewer under 65 participants
assigned to the treatment arm, then by a symmetric argument an efficient estimator adjusts
for this by increasing the unadjusted estimate of ∆. The overall impact of such adjustments
across many hypothetical trials, is to remove the variance caused by chance imbalances across
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arms in the stratum W = 1. This is, intuitively, why there is an efficiency gain when γ= 0.
Now consider py = 1 and the opposite extreme of maximum treatment effect heterogeneity
(γ= 2R2W ), which occurs when E(Y |A= 1,W )+E(Y |A= 0,W ) equals the constant E(Y |A=
1)+E(Y |A= 0). An analogous argument (given in Section D of the Supplementary Material)
to the previous paragraph shows that adjustment for chance imbalances in W leads to equal
changes (in the same direction) in the estimated means in each arm; the net impact is that
the difference between estimated means across arms is not changed (due to cancellation).
Adjustment has no impact in this case, and leads to no variance reduction.
Above, we considered py = 1, i.e., no pipeline participants. We now fix R
2
W > 0 and γ > 0,
and consider the impact of decreasing py from 1 to 0. This leads to increased ARE because
an efficient estimator can extract information from pipeline participants if γ > 0; in contrast,
the unadjusted estimator does not use any information from pipeline participants. Intuition
for why γ > 0 is necessary in order for pipeline participant information to be useful is given
in Section D of the Supplementary Material.
3.3 Impact of a Short-term Outcome on Precision Gain
To isolate the impact of a short-term outcome L on precision gain, we set R2W = 0 in (6)
so that only L is prognostic. The precision gain from adjusting for short-term outcome L
depends on two factors: the proportion of variance in Y explained by L after accounting for
W (R2L|W ), and the proportion of participants with Y observed among those with L observed
(py/pl). In Figure 2, we plot the ARE against py/pl, and consider two values of R
2
L|W .
Smaller py/pl and larger R
2
L|W generally increase the precision gain from adjusting for
L; this is because L adds value just for participants with L but not Y observed, and R2L|W
quantifies the prognostic value of L beyond the variance in Y explained by W . When there
are no pipeline participants, which would occur at the end of a trial with no early stopping
or dropout, we have py/pl = 1 and the ARE is 1, i.e., adjusting for L is useless. This is
because adjusting for L helps by, in each arm separately, accounting for chance imbalances
between the participants with Y observed and the participants with L but not Y observed;
when py/pl = 1, these groups are identical and no adjustment can be made.
Recall that we are operating in the semiparametric model defined by Assumptions 1-3; in
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Figure 2: Asymptotic relative efficiency between an efficient estimator and the unadjusted
estimator for estimating ∆, when only the short-term outcome L is prognostic (R2W = 0 in
both curves). The solid line corresponds to a higher prognostic value R2L|W = 0.25 and the
dashed line corresponds to a lower prognostic value R2L|W = 0.1.
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particular, we are not making any assumptions about the relationships among the variables
(Y,A,L). Therefore, we cannot adjust for observed imbalances in L between arms A∈{0,1},
since these imbalances may be due to the impact of arm assignment.
Given fixed R2L|W > 0, larger py/pl decreases the precision gain from adjusting for L, as
seen in Figure 2. In a trial with constant enrollment rate and dL<dY , the precision gain from
adjusting for L typically attenuates at later stages of a group sequential design due to py/pl
being nondecreasing over time. In the case where missingness is only due to administrative
censoring, py/pl starts at 0 at time dL and eventually becomes 1 after enrollment stops and
enough time has elapsed for all enrolled participants to have Y observed.
3.4 Comparison of Equally Prognostic Baseline Variable and Short-
term Outcome
For any q : 0<q≤ 1, we compare the ARE between two cases: R2W = q,R2L|W = 0 (only base-
line variable prognostic) and R2W = 0,R
2
L|W = q (only short-term outcome prognostic). The
ARE in the former case is larger or equal to that in the latter case. Equality occurs if and
only if pl = 1 and treatment effect heterogeneity in the first case is the maximum possible
(γ= 2R2W = 2q), as proved in Section H.8 of the Supplementary Material. Intuition for this
is given in Section D of the Supplementary Material. The equality can be seen graphically in
that the two lines in Figure 2 (corresponding to prognostic value 0.25 and 0.1) are identical
to the two corresponding lines in Figure 1 with γ= 2R2W ; the horizontal axes of the two
figures are identical in the special case of pl = 1.
4 Estimator that Adjusts for Baseline Variables and
Short-term Outcomes
4.1 Targeted Minimum Loss-Based Estimator
The targeted minimum loss-based estimator (TMLE) of van der Laan and Gruber (2012),
which builds on the ideas of Robins and Rotnitzky (1992); Scharfstein et al. (1999); Robins
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(2000); Bang and Robins (2005); van der Laan and Rubin (2006), is implemented in the R
package ltmle (Lendle et al., 2017). We use it to estimate ∆ and call it the adjusted estimator.
Our implementation of this TMLE for a binary outcome Y involves fitting logistic regres-
sion working models. Such models are fit first for the conditional probabilities of censoring
given the observed history before censoring: P (CL = 1 |A,W ) and P (CY = 1 |L,A,W ). We
also fit such a model for study arm assignment P (A= 1 |W ). Lastly, we fit logistic regression
models for E(Y |L,A,W ) and for E(Y |A,W ), given the corresponding observed histories; we
refer to these as outcome regression models. The last model is fit using sequential regression,
an idea from Robins (2000); Bang and Robins (2005); see our R code (Github link given at
end of paper) for the implementation of the software of Lendle et al. (2017) that we used.
All models involve an intercept and main terms for each regressor variable. Each regression
is performed using all participants for whom the relevant variables are uncensored. For a
continuous-valued outcome Y , linear outcome regression models could be used or, if the
outcome is bounded then it can be rescaled to the interval [0,1] and logistic regression can
be used as described by Gruber and van der Laan (2010).
The adjusted estimator initially uses the aforementioned regression model fits. It then
updates each outcome regression model by adding a new covariate built from the other model
fits, as described by van der Laan and Gruber (2012). The final estimator of the average
treatment effect ∆ is based on the updated outcome regression model fit of E(Y |A,W ). It
is computed by first generating a prediction Ya,i of the outcome Y under each hypothetical
assignment to arm a∈{0,1} for each participant i by substituting W =Wi and A= a into
this model fit. The estimator of ∆ is (1/n)
∑n
i=1(Y1,i−Y0,i).
Assumptions 1-3 from Section 2 imply that the censoring models and the model for
P (A= 1|W ) are correctly specified. The results of van der Laan and Gruber (2012, Section
4) imply that the adjusted estimator is a consistent estimator of the average treatment effect
∆. This holds regardless of the correctness of the outcome regression models. That is,
these models could be arbitrarily misspecified and still the adjusted estimator converges in
probability to ∆ as sample size goes to infinity. If the outcome regression models are correct,
then the adjusted estimator achieves the asymptotic variance lower bound in (1), in which
case it is semiparametric, locally efficient (van der Laan and Gruber, 2012, Section 4). Other
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estimators with the above properties include the augmented, inverse probability of treatment
(and censoring) estimators of Robins (2000) and Bang and Robins (2005).
4.2 Approximating the Relative Efficiency between the Adjusted
Estimator and the Unadjusted Estimator
We focused on the asymptotic relative efficiency between an efficient estimator and the
unadjusted estimator in Section 3. To connect our results regarding efficient estimators to
the adjusted estimator, we use results from van der Laan and Gruber (2012, Section 5.3).
These results imply that if all regression models used in the TMLE are correctly specified,
then plugging the corresponding model fits into the formulas (2)-(5) and then using these
estimates of γ,R2W ,R
2
L|W in (6) results in a consistent estimator of the ARE (called the
plug-in estimator). This estimator of the ARE is asymptotically conservative, meaning that
the AREs may be underestimated but not overestimated, if the models for censoring and
for P (A= 1|W ) are correctly specified; since these models are correct under Assumptions
1-3, it follows that the plug-in estimator can serve as a (possibly conservative) asymptotic
approximation to the ARE between the adjusted estimator and the unadjusted estimator.
Denote by Ê(Y |X =x) the predicted value of E(Y |X =x) from a model fit. Let V̂ar(·)
denote the sample variance over participants from both arms, and V̂ara(·) denote the sample
variance over participants from arm a. We estimate R2W , R
2
L|W , and γ, respectively, by
R̂2W =
∑
a∈{0,1}V̂ar{Ê(Y |W,A= a)}∑
a∈{0,1}V̂ara(Y )
,
R̂2L|W =
∑
a∈{0,1}V̂ara{Ê(Y |W,L,A= a)− Ê(Y |W,A= a)}∑
a∈{0,1}V̂ara(Y )
,
γ̂=
V̂ar{Ê(Y |W,A= 1)− Ê(Y |W,A= 0)}∑
a∈{0,1}V̂ara(Y )
.
In Sections 5-6 when calculating the conditional expectations Ê in the formulas for R̂2W and
R̂2L|W , we used logistic regression model fits with main terms. When calculating γ̂, we used
similar model fits except including interactions, since we wanted to give an opportunity to
detect treatment effect heterogeneity. The estimated R-squared quantities above are relevant
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for continuous and binary outcomes in measuring the precision gain from adjustment when
estimating ∆; this generalizes an idea from Moore and van der Laan (2009), who give an
R-squared formula related to R̂2W except that it marginalizes over A.
5 Applying Precision Gain Formula to Trial Data
5.1 Trial Example: MISTIE-II
MISTIE-II is a Phase II randomized clinical trial evaluating a new surgical treatment for
intracerebral hemorrhage. The treatment is called Minimally-Invasive Surgery Plus rt-PA for
Intracerebral Hemorrhage Evacuation, abbreviated as MISTIE (Hanley et al., 2016). In the
MISTIE-II dataset, the primary and short-term outcomes of each participant correspond to
the Modified Rankin Scale (mRS), measured at different times after enrollment. We use the
variables in Table 1. The primary outcome Y is a binary indicator of a successful outcome
(mRS≤ 3) at 180 days after enrollment. The short-term outcomes L(1) and L(2) are the
indicators of mRS no larger than 4 at 30 and 90 days after enrollment, respectively. The
cutoff 4 for L(1) and L(2) was chosen because there were relatively few participants with
mRS 3 or less at 30 or 90 days after enrollment. The treatment assignment indicator A
denotes whether a participant is assigned to the surgical treatment (A= 1) or to standard
of care (A= 0). Baseline variables W (1)-W (4) are age (dichotomized at 65 years), NIHSS
(NIH Stroke Scale total score, quantifying stroke-caused impairment), ICH (intracerebral
hemorrhage volume), and GCS (Glasgow Coma Scale), all measured before randomization.
The baseline variables (except for age) are treated as continuous variables in the regression
models. The dataset has 100 participants.
We let W full = (W (1),W (2),W (3),W (4)) and Lfull = (L(1),L(2)). These variables are used
in constructing data generating distributions for our simulations in Section 6. However,
only the smaller subsets of variables W = (W (1),W (4)) and L=L(1) are made available to
the adjusted estimator (both in Section 5.2 and 6). We included the “extra” variables
W (2),W (3),L(2) (which the adjusted estimator does not have access to) in our data generating
distributions for simulations so that the regression models used by the adjusted estimator
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Table 1: Variables that we use from the MISTIE-II dataset. Ordinal-valued basline variables
below are treated as continuous in our regression models.
Name Description
W (1) baseline age (years), dichotomized at ≤ 65
W (2) baseline NIHSS, ordinal
W (3) baseline ICH, ordinal
W (4) baseline GCS, ordinal
A treatment indicator, 1 being MISTIE
L(1) mRS at 30 days, dichotomized by thresholding at ≤ 4
L(2) mRS at 90 days, dichotomized by thresholding at ≤ 4
Y mRS at 180 days, dichotomized by thresholding at ≤ 3
will be misspecified; this was done since we expect at least some misspecification to occur in
practice.
5.2 Approximate Precision Gain by Using the Adjusted Estimator
on MISTIE-II Data
Applying the method in Section 4.2 to the MISTIE-II data, the estimated R-squared quanti-
ties are R̂2W = 0.36, R̂
2
L|W = 0.08, and γ̂= 0.02. This indicates that the baseline variables are
strongly prognostic, that (after accounting for the baseline variables) the short-term outcome
L is only mildly prognostic, and that there is little (if any) treatment effect heterogeneity.
At the end of a trial, if every participant has Y observed, we have pl = py = 1. Substi-
tuting these and the estimated values R̂2W ,R̂
2
L|W ,γ̂ into (6) gives an approximate ARE of
1.53 comparing the TMLE versus the unadjusted estimator. If instead there had been no
treatment effect heterogeneity (γ̂= 0), then the approximate ARE would be slightly larger
(1.55), assuming R̂2W and R̂
2
L|W remain fixed. Now consider a hypothetical interim analysis
where 80% of the enrolled participants have Y observed and 95% of the enrolled partici-
pants have L observed (e.g., at the 3rd interim analysis of the group sequential design with
nmax = 480 considered in Section 6.3; see Table B.1 in the Supplementary Material). Then
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we have py = 0.8, pl = 0.95, and the approximate ARE is 1.56.
Equivalently, in each of the three aforementioned situations, the adjusted estimator ap-
proximately reduces the required sample size to achieve a desired power by 35%, 36%, and
36%, respectively, compared to the unadjusted estimator. (The asymptotic sample size re-
duction is computed as 1−1/ARE as described in Section F of the Supplementary Material.)
These are all quite similar, which is primarily due to the relatively small values of γ̂ and
R̂2L|W . The magnitudes of the AREs above are not unusual in the MISTIE-II population–see
Optimising the Analysis of Stroke Trials (OAST) Collaboration (2009)–and result from some
baseline variables (especially NIHSS) being strongly prognostic for the outcome.
Approximations of the ARE as above can be applied to trial planning, where one may
use previous data to estimate the variance explained by baseline variables and short-term
outcomes and the treatment effect heterogeneity, and use (6) to get a rough projection of the
precision gain from adjusting for baseline variables and short-term outcomes. If treatment
effect heterogeneity is difficult to estimate a priori, one could use γ= 0 as the best case
scenario (no treatment effect heterogeneity, corresponding to maximal precision gain), with
the expectation that γ > 0 will result in attenuated precision gain.
A conservative approach is to assume no precision gain when selecting the initial sam-
ple size per stage, but then use preplanned sample-size re-estimation (using the estimated
variance) to potentially shrink the per-stage sample size to reflect the estimated precision
gains based on accrued data. Such adaptations based on estimating a nuisance parameter
are generally acceptable to regulators such as the U.S. Food and Drug Adminsitration (FDA,
2016; FDA, 2018). This approach has important limitations given in Section 7.
6 Simulations of Group Sequential Design
6.1 Data Generating Distributions for Simulated Trials Based on
MISTIE-II
We conducted simulation studies to assess how good of an approximation is provided by the
precision gain formula (6), and to examine the sample size reduction by using the adjusted
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versus unadjusted estimator in a group sequential design. In order to mimic key features of
the MISTIE-II trial, we use a resampling-based algorithm to generate participants for our
simulated trials. This algorithm generates simulated trials with the following properties:
(i) The treatment assignment is independent of baseline variables.
(ii) The relative efficiency between the adjusted estimator and the unadjusted estimator
is similar to that calculated directly from the MISTIE-II dataset.
We define eight data generating distributions, called “settings”. The goal is to consider
four situations involving W and/or L being prognostic or not for Y ; these are denoted by
prognW,L (both prognostic), prognW (only W prognostic), prognL (only L prognostic), and
progn∅ (neither prognostic). For each of these four situations (called “prognostic settings”),
we construct distributions with the following two average treatment effects: ∆ = 0 (no effect)
or ∆ = 0.122 (benefit equal to the unadjusted estimate from the MISTIE-II dataset). Details
of the data generating algorithm for the eight settings are in Section C of the Supplementary
Material. Table 2 gives the approximate R-squared and γ values for the eight settings. The
only source of missing data in our simulations is administrative censoring, i.e., participants
who enrolled but have not been in the trial long enough to have outcomes measured.
Table 2: Approximate R-squared and γ for each of the eight data generating distributions
(settings) in our simulation study, computed by simulating 106 participants under each
distribution and computing R̂2W ,R̂
2
L|W ,γ̂, respectively.
prognW,L prognW prognL progn∅
∆ = 0 ∆ = 0.122 ∆ = 0 ∆ = 0.122 ∆ = 0 ∆ = 0.122 ∆ = 0 ∆ = 0.122
R2W 0.35 0.36 0.35 0.36 0 0 0 0
R2L|W 0.08 0.07 0 0 0.30 0.30 0 0
γ 0 0.01 0 0.01 0 0 0 0
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6.2 Group Sequential Trial Design Analysis Timing and Early
Stopping Rule
We assume that dL = 30 days and dY = 180 days. The goal is to control Type I error at level
0.025 and to have at least 80% power to reject the null hypothesis H0 : ∆≤ 0 when ∆ = 0.122.
We used the group sequential design framework in Hampson and Jennison (2013), which
involves interim analyses where a choice is made to stop or continue enrollment; if enrollment
is stopped, then one waits until all pipeline participants complete the trial and then a
hypothesis test (called a decision analysis) is conducted. Full details of the design are in
Supplementary Material B.1.
Denote by K the total number of stages. We set K = 5 stages in our simulated trials.
Participants were enrolled at the constant rate of 140 participants per year based on the
projection for the enrollment rate in the MISTIE-III trial (Hanley, 2016). Given the max-
imum sample size nmax, the timing of interim analyses is chosen such that for 1≤ k≤ 4, at
the k-th interim analysis there are (k/K)nmax participants with Y observed.
For either estimator the corresponding Wald statistics at different analysis times have
(asymptotically) a multivariate normal distribution, where the information at a given analy-
sis time is the reciprocal of the estimator variance. (This relies on Assumptions 1-3 and holds
regardless of the correctness of the outcome regression models used in the adjusted estima-
tor.) The covariance matrix can be estimated, e.g., using the nonparametric bootstrap. To
reduce the computational burden in our simulation studies, for any data generating distri-
bution and nmax we precompute the covariance matrix of our statistics at different analysis
times, which is then used to determine stopping boundaries. The efficacy/futility stop-
ping boundaries at each stage are calculated using the error spending approach presented
in Supplementary Material B.2. We used error spending functions f(t) = 0.025min(t2,1) for
Type I error and g(t) = 0.2min(t2,1) for Type II error, where t denotes the information time
(observed information divided by maximum information).
For each combination of prognostic setting (prognW,L,prognW ,prognL,progn∅) and esti-
mator (unadjusted or adjusted), we use binary search to find the minimum total sample size
nmax required to achieve approximately 80% power under ∆ = 0.122 at 0.025 Type I error us-
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ing the group sequential design. In practice, this could be approximated from accruing data
by estimating the variance of the adjusted estimator and then using sample size re-estimation
to set nmax. However, we assumed that this was known in order to reduce the computational
burden. For the unadjusted estimator, in every setting we let nmax be 480. For the adjusted
estimator, nmax is set to be 300 under all settings with prognW,L and prognW , and 480 under
all settings with prognL and progn∅. We simulated 50,000 trials under each of the eight
settings. The number of accrued participants, error spending functions, and the stopping
boundaries for each analysis are listed in Table B.2 in the Supplementary Material.
6.3 Simulation Results: Sample Size Reduction from Adjustment
Table 3 lists the simulation-based nmax, Type I error (obtained under ∆ = 0), power (obtained
under ∆ = 0.122), and the expected sample size (ESS) for each of the eight settings for each
estimator. For each setting, the empirical Type I error rate is controlled at 0.025 and
the power is approximately 80%. ESS is calculated as the number of enrolled participants
when the trial stops, averaging over 50,000 simulations. The performance of the unadjusted
estimator is the same under all prognostic settings and is summarized in the first row.
Compared to the unadjusted estimator, the adjusted estimator substantially reduces the
sample size when the baseline variables are prognostic. In particular, comparing the first
row (unadjusted) versus the third row (adjusted prognW ), the adjusted estimator reduces
the maximum sample size from 480 to 300, the expected sample size under ∆ = 0 from 318
to 227, and the expected sample size under ∆ = 0.122 from 382 to 260. The sample size
reduction due to the prognostic short-term outcome is very small. When neither W nor L
is prognostic (progn∅), performance of the two estimators is similar.
6.4 Simulation Results: Relative Efficiency
In this subsection, we simulated trials with no early stopping, i.e., each simulated trial always
enrolls nmax participants and continues follow-up until all participants have Y observed. We
then look back at each simulated trial and compute what each estimator’s value would be
at each of the interim and decision analysis times. At any analysis time, the number of
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Table 3: The maximum sample size (nmax) and empirical Type I error, power, and expected
sample size (ESS) under ∆ = 0 and ∆ = 0.122 for each estimator under each prognostic
setting. The nmax was chosen for each prognostic setting in order to achieve approximately
80% power under ∆ = 0.122.
Estimator Progn. set. nmax Type I error Power ESS(∆ = 0) ESS(∆ = 0.122)
unadjusted - 480 0.0250 0.811 318 382
adjusted prognW,L 300 0.0254 0.791 225 259
prognW 300 0.0256 0.805 227 260
prognL 480 0.0253 0.805 309 375
progn∅ 480 0.0248 0.811 321 384
participants with Y observed, L observed, and only (A,W ) observed, respectively, is fixed;
therefore, we can make a direct comparison between the ratio of estimator variances in our
simulations and the predicted ARE from our formula (which assumes constant pl,py).
In order to make direct comparisons between estimators at the same sample size, we
change (just for this subsection) the setting of nmax. The maximum sample size nmax is set
to be 300 under prognW,L and prognW , and is set to 480 under prognL and progn∅. Under
each setting the same nmax is used for both the unadjusted estimator and the adjusted
estimator.
Table 4 lists the approximate, asymptotic relative efficiency (ARE) computed by evalu-
ating (6) but with conditional expectations replaced by empirical estimates as discussed in
Section 4.2, and the relative efficiency (RE) from simulation. Under most settings, the ARE
predicted by the theory is similar to the RE computed from the simulation. There are some
discrepancies between these at the earlier analysis times. We think that this is due to the
relatively small sample sizes at these analysis times compared to the number of variables
adjusted for, which can lead to model overfit and so reduced performance of the adjusted
estimator. For example, at interim analysis 1 under prognW,L there are only 60 participants
with the primary outcome observed but 4 variables get adjusted for in the regression model
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for E(Y |W,A,L); this violates the rule of thumb that one should have at least 20 observations
per term in the regression model. We discuss possible remedies for this in Section 7.
A comparison between prognW (when only W is prognostic) and prognL (when only L
is prognostic) shows that there is a much larger precision gain in the former case. This is
despite the fact that W and L have roughly similar prognostic values for Y marginally, as
shown in Table 2. The reason, as discussed in Sections 3.2-3.4, is that there is relatively
little treatment effect heterogeneity, which means that the baseline variables contribute to
precision gains in two ways: allowing adjustment for chance imbalances (i) between study
arms among the participants with Y observed, and (ii) between the full sample and the
subset with Y observed. The short-term outcome can only contribute in the second way,
and so may lead to smaller gains. Under prognL, comparing interim analyses to decision
analyses shows that L improves estimation precision only at interim analyses (i.e., when
there are pipeline participants), which is in line with our theoretical results.
7 Discussion
We considered independent censoring, and the only source of missing data in our simulations
was administrative censoring. If outcomes are missing at random (Rubin, 1976), then the
adjusted estimator may still be consistent under correct specification of certain working
models, while the unadjusted estimator may be biased. If dropout is missing not at random
(Rubin, 1976), then both estimators may be inconsistent and our formulas will not work.
The theoretical ARE can be larger than the simulation-based ARE, especially at the
early interim analyses. One reason is that in practice there is a finite sample penalty for ad-
justment (for each degree of freedom in the models fit) that is not reflected in the theoretical
calculations, and that dissipates as sample size grows. This issue may be mitigated by only
scheduling interim analyses for times when at least 50% of the participants have primary
outcomes observed, and by constraining the number of variables adjusted for such that one
has at least 20 participants with primary outcomes observed per variable.
The sample size reductions due to improved precision from adjustment came primarily
from selecting smaller nmax. Since the prognostic value of variables is typically not precisely
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Table 4: Comparison of the asymptotic relative efficiency (ARE) predicted by Theorem 2 to
the relative efficiency (RE) from simulated trials, at each analysis time. Top half is under
∆ = 0; bottom half is under ∆ = 0.122. The maximum sample size nmax is set to be 300
under prognW,L and prognW , and is set to 480 under prognL and progn∅. Under each setting
the same nmax is used for both the unadjusted estimator and the adjusted estimator. The
simulated RE is computed from 50,000 simulated trials.
ARE from theory RE from Simulation
prognW,L prognW prognL progn∅ prognW,L prognW prognL progn∅
under ∆ = 0
Interim
Analysis
1 1.63 1.54 1.13 1.00 1.49 1.41 1.08 0.96
2 1.59 1.54 1.07 1.00 1.54 1.49 1.06 0.98
3 1.58 1.54 1.05 1.00 1.54 1.51 1.04 0.99
4 1.57 1.54 1.04 1.00 1.54 1.51 1.04 0.99
Decision
Analysis
1 1.53 1.53 1.00 1.00 1.49 1.51 0.99 0.99
2 1.53 1.53 1.00 1.00 1.50 1.53 0.99 0.99
3 1.53 1.53 1.00 1.00 1.51 1.52 0.99 0.99
4 1.53 1.53 1.00 1.00 1.51 1.54 1.00 1.00
5 1.53 1.53 1.00 1.00 1.51 1.54 1.00 1.00
under ∆ = 0.122
Interim
Analysis
1 1.64 1.56 1.12 1.00 1.49 1.43 1.08 0.96
2 1.61 1.55 1.07 1.00 1.56 1.51 1.06 0.98
3 1.59 1.55 1.05 1.00 1.57 1.53 1.04 0.99
4 1.58 1.55 1.04 1.00 1.57 1.53 1.03 0.99
Decision
Analysis
1 1.55 1.55 1.00 1.00 1.51 1.52 0.99 0.99
2 1.55 1.55 1.00 1.00 1.53 1.53 0.99 0.99
3 1.55 1.55 1.00 1.00 1.53 1.53 0.99 0.99
4 1.55 1.55 1.00 1.00 1.54 1.54 1.00 1.00
5 1.55 1.55 1.00 1.00 1.54 1.54 1.00 1.00
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known before the trial starts, one may use a preplanned rule for sample size re-estimation
to set nmax based on accruing data. First, the original, maximum sample size is set conser-
vatively assuming no gains from adjustment. During the trial the asymptotic variance of
the adjusted estimator is estimated and nmax is set to be the sample size for which the de-
sired power is achieved when ∆ equals the a priori specified, clinically meaningful, minimum
treatment effect. The sample size re-estimation should only be conducted after a sufficient
number of participants have had their primary outcomes measured, e.g., when roughly 50%
of the originally planned sample size have this measured.
This approach is only feasible if the delay time dY is not too long compared to the
enrollment rate (otherwise the originally planned sample size will all be enrolled before a
sufficient number of primary outcomes are observed). This was feasible in the MISTIE trial
context with dY = 180 days and enrollment rate 140 per year, since sample size re-estimation
could be done at 2.1 years. At this time, 230 (48%) of the originally planned sample size
(480) have primary outcomes observed. So restricting to approximately 300 participants (the
required nmax when W is as prognostic as in the MISTIE-II data) is possible.
A limitation of our simulation study is that we precomputed nmax for each setting, in
order to save computation time. In practice, this would be calculated as a function of the
estimated variance using accruing data in the trial. A future area of research is to run
simulation studies to evaluate the resulting impact on power and sample size.
R code (R Core Team, 2018) for our simulations can be downloaded at https://github.
com/tqian/gst_tmle.
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Supplementary Material
In Section A, we discuss the relationship between asymptotic relative efficiency and sample
size reduction for a Wald test of a single stage trial. In Section B, we present the group
sequential design used in the simulation studies in Section 6. In Section C, we specify the
data generating distribution used in the simulation studies in Section 6. Intuition for the
impact of treatment effect heterogeneity on precision gains is given in Section D. In Section
E, we provide additional theoretical results regarding the precision gain from adjusting for
prognostic baseline variables, when the baseline variable is either purely predictive or purely
prognostic. In Section F, we provide theoretical results regarding the precision gain from
adjusting for prognostic baseline variables and the short-term outcome, when the parameter
is E(Y |A= a) for each a∈{0,1} (rather than the average treatment effect). Simulations to
evaluate the theory in Section F are provided in Section G. Section H includes proofs of the
results in the main paper as well as results in Section E and Section F. Auxiliary lemmas
that are used in the proofs in Section H are themselves proven in Section I.
A Relationship between asymptotic relative efficiency
and sample size reduction for a Wald test of a single
stage trial
Consider one-sided Wald tests of the null hypothesisH0 : ∆≤ 0 versus the alternativeH1 : ∆>
0, using RAL estimators ∆̂1 and ∆̂2, respectively (where the test statistics are the estimators
divided by their standard errors). The asymptotic relative efficiency can be interpreted as
the limit as sample size goes to infinity of the inverse of the ratio of the required sample
sizes for the two estimators to achieve a given power at local alternatives (van der Vaart,
2000, Section 8.2). For example, ARE(∆̂1,∆̂2) = 1.2 means that by using ∆̂1 instead of ∆̂2,
the required sample size is reduced by 1−1/1.2≈ 17% asymptotically.
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B Full Description of Group Sequential Design Used
in Simulation
Components of the group sequential design used in simulation are presented in the following
order: the multiple testing procedure (Section B.1), the computation of the test boundaries
(Section B.2), the sample size at each analysis for the simulated trials (Section B.3), and
the value of Type I error and Type II error spent and the testing boundary at each analysis
(Section B.4).
B.1 Multiple Testing Procedure
In the simulation studies in Section 6 we use the group sequential test from Hampson and
Jennison (2013) with K stages. Given α,β ∈ (0,1), the design goal is to control the Type I
error rate at level α and have power 1−β at alternative ∆ = δ > 0. Such a group sequential
test can terminate enrollment at an interim analysis, and if such early stopping happens
follow-up continues until all pipeline participants have Y observed before conducting a deci-
sion analysis to reject or accept H0. For each stage k, denote by Sk and S˜k the test statistics
at the kth interim analysis (where the decision to stop or continue enrollment occurs) and
the kth decision analysis (where the hypothesis test is conducted), respectively; let uk and lk
denote the efficacy and futility boundaries for terminating enrollment at interim analysis k,
and let ck denote the critical value for the corresponding decision analysis. These are used
in the group sequential testing procedure below, reproduced from Hampson and Jennison
(2013, Figure 1):
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
At interim analysis k= 1,...,K−2,
if Sk≤ lk or Sk≥uk stop recruitment and proceed to decision analysis k;
otherwise continue recruitment and proceed to interim analysis k+1.
At interim analysis K−1,
if SK−1≤ lK−1 or SK−1≥uK−1 stop recruitment and proceed to decision analysis K−1;
otherwise complete recruitment and proceed to decision analysis K.
At decision analysis k= 1,...,K,
if S˜k≥ ck reject H0;
if S˜k<ck accept H0.
B.2 Computation of Test Boundaries
Following Hampson and Jennison (2013), consider a Type I error spending function f(·)
and Type II error spending function g(·), which are non-decreasing with f (0) = g(0) = 0 and
f (t) =α and g(t) = β for t≥ 1. The maximum information level Imax is chosen depending
on the power goal and the error spending functions. Denote by Ik and I˜k the information
levels at the k-th interim analysis and decision analysis, respectively. Denote by Ck = (lk,uk)
the critical region at interim analysis k, 1≤ k≤K. The test boundaries uk, lk, and ck are
calculated by (12)-(15) in Hampson and Jennison (2013, Section 4.1.1), and we paraphrase
as follows. Let u1 and l1 be the solutions to
P (S1≥u1;∆ = 0) = f(I1/Imax) and P (S1≤ l1;∆ = δ) = g(I1/Imax).
For 2≤ k≤K−1, uk is the solution to
P (S1 ∈C1,...,Sk−1 ∈Ck−1,Sk≥uk;∆ = 0) = f(Ik/Imax)−f(Ik−1/Imax), (B.1)
and lk is the solution to
P (S1 ∈C1,...,Sk−1 ∈Ck−1,Sk≤ lk;∆ = δ) = g(Ik/Imax)−g(Ik−1/Imax). (B.2)
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For 1≤ k≤K−1, the critical value ck is the solution to
P (S1 ∈C1,...,Sk−1 ∈Ck−1,Sk≥uk,S˜k<ck;∆ = 0)
=P (S1 ∈C1,...,Sk−1 ∈Ck−1,Sk≤ lk,S˜k≥ ck;∆ = 0).
And the critical value cK for the last stage is the solution to
P (S1 ∈C1,...,SK−1 ∈CK−1,S˜K ≥ cK ;∆ = 0) =α−f(IK−1/Imax).
B.3 Sample Size at Each Analysis
Table B.1 lists the sample size and analysis timing of the group sequential designs with
nmax = 480 and nmax = 300 used in Section 6.4. For 1≤ k≤ 4, Analysis k indicates interim
analysis at stage k and k∗ indicates the corresponding decision analysis if enrollment is
early stopped at that stage. Analysis 5∗ indicates the final decision analysis. There is not
any interim analysis for the final stage. Fully observed participants are those with W,L,Y
observed; partially observed participants are those with W,L but not Y observed. The three
groups of participants listed in Table B.1 are inclusive of all enrollees and mutually exclusive.
B.4 Type I Error and Type II Error Spent and Testing Boundary
Table B.2 lists the Type I error per stage f(Ik/Imax)−f(Ik−1/Imax), Type II error per stage
g(Ik/Imax)−g(Ik−1/Imax), and the testing boundaries at each stage under different settings
used in the simulation studies. Given any prognostic setting prognW,L,prognW ,prognL,progn∅
and estimator pair, the designs are the same for ∆ = 0 and ∆ = 0.122.
C Resampling-based Algorithm to Simulate Trial Data
For the data generating distribution to have the two properties in Section 6.1, we design the
algorithm to generate a simulated trial of n independent and identically distributed samples
from the 100 participants in MISTIE-II dataset. Recall that the three properties are:
(i) The treatment assignment is independent of baseline variables.
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Table B.1: Analysis time and sample size at each interim and decision analysis for group
sequential designs with nmax = 480 and nmax = 300. For 1≤ k≤ 4, Analysis k indicates interim
analysis and k∗ indicates the corresponding decision analysis if enrollment is early stopped.
Analysis 5∗ indicates the final decision analysis.
Analysis 1 1∗ 2 2∗ 3 3∗ 4 4∗ 5∗
Design with nmax = 480
Time (year) 1.2 1.7 1.9 2.4 2.6 3.0 3.2 3.7 3.9
# Fully observed (W,L,Y ) 96 165 192 261 288 357 384 453 480
# Partially observed (W,L) only 57 0 57 0 57 0 57 0 0
# Pipeline with only W observed 12 0 12 0 12 0 12 0 0
Design with nmax = 300
Time (year) 0.9 1.4 1.4 1.8 1.8 2.3 2.2 2.6 2.6
# Fully observed (W,L,Y ) 60 129 120 189 180 249 240 300 300
# Partially observed (W,L) only 57 0 57 0 57 0 57 0 0
# Pipeline with only W observed 12 0 12 0 12 0 3 0 0
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Table B.2: Type I error per stage f(Ik/Imax)−f(Ik−1/Imax), Type II error per stage
g(Ik/Imax)−g(Ik−1/Imax), and boundaries for the designs in the different settings used in
Section 6.3.
Analysis (k) 1 2 3 4 5
TMLE under prognW,L, nmax = 300
Type I error per stage ×10−3 0.9 3.2 5.1 7.2 8.6
Type II error per stage ×10−3 7.5 25.4 41.1 57.3 68.6
Efficacy boundary at interim analysis (uk) 3.11 2.71 2.47 2.27 -
Futility boundary at interim analysis (lk) -1.20 -0.08 0.70 1.36 -
Critical value at decision analysis (ck) 1.30 1.54 1.74 1.91 2.07
TMLE under prognW , nmax = 300
Type I error per stage ×10−3 0.8 2.9 5.0 7.0 9.3
Type II error per stage ×10−3 6.5 23.4 40.1 55.8 74.1
Efficacy boundary at interim analysis (uk) 3.16 2.73 2.48 2.28 -
Futility boundary at interim analysis (lk) -1.26 -0.14 0.66 1.33 -
Critical value at decision analysis (ck) 1.32 1.55 1.75 1.91 2.06
TMLE under prognL, nmax = 480
Type I error per stage ×10−3 1.2 3.2 5.3 7.5 7.8
Type II error per stage ×10−3 9.3 25.8 42.6 60.2 62.1
Efficacy boundary at interim analysis (uk) 3.05 2.68 2.44 2.24 -
Futility boundary at interim analysis (lk) -0.99 0.04 0.80 1.47 -
Critical value at decision analysis (ck) 1.24 1.50 1.72 1.91 2.06
TMLE under progn∅, nmax = 480
Type I error per stage ×10−3 0.9 2.9 5.1 6.9 9.3
Type II error per stage ×10−3 7.3 22.9 40.6 54.9 74.3
Efficacy boundary at interim analysis (uk) 3.12 2.73 2.47 2.28 -
Futility boundary at interim analysis (lk) -1.16 -0.08 0.72 1.37 -
Critical value at decision analysis (ck) 1.24 1.50 1.72 1.91 2.04
Unadjusted estimator, nmax = 480
Type I error per stage ×10−3 1.0 3.0 4.9 6.9 9.2
Type II error per stage ×10−3 7.8 24.1 39.6 54.9 73.6
Efficacy boundary at interim analysis (uk) 3.10 2.72 2.48 2.29 -
Futility boundary at interim analysis (lk) -1.37 -0.43 0.24 0.82 -
Critical value at decision analysis (ck) 1.18 1.36 1.53 1.67 2.11
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(ii) The relative efficiency between the adjusted estimator and the unadjusted estimator in
the simulated data is similar to that calculated directly from the MISTIE-II dataset.
Briefly, the algorithm ensures property (i) by adding a “twin” with identical baseline variables
and opposite treatment assignment to each participant in the MISTIE-II dataset. The
variables Lfull and Y for each “twin” are then generated using regression model fits. The
original MISTIE-II data and the set of “twins” results in a 200 participant data set. This
is done once, before any of our simulations are conducted. To generate each simulated data
set, we resample participant vectors from this 200 participant data set with replacement
and then make modifications to the replicate data set depending on the desired simulation
setting. Details of the algorithm are given below.
Step 1: Construct a set of 100 pairs of “twins”. We start with the 100-participant
MISTIE-II dataset, and we augment the data with a hypothetical “twin” for each participant.
A “twin” has identical baseline variables as the original participant, but opposite treatment
assignment. We fit logistic regression models for L(1) on (W full,A), for L(2) on (W full,A,L(1)),
and for Y on (W full,A,L(1),L(2)), using the original 100 participants in MISTIE-II dataset.
The preliminary Li and Yi of each newly added twin are then predicted based on these
logistic regression models by rounding the predicted success probability to be 0 or 1. The
indicator of whether a participant is an original participant in the MISTIE-II data set or a
hypothetical twin is included as a variable in this augmented data set of 200 participants,
which will be used in Step 2. Step 1 is only done once at the beginning of the simulation.
Step 2: Sample n participants from the augmented data set with 200 participants and cal-
ibrate the treatment effect on the sampled participants. We sample n participants uniformly
with replacement from the augmented dataset constructed in Step 1. Then, for each par-
ticipant in the n participants whose “hypothetical twin indicator” is true, with probability
0.03 we reset its Yi to equal Ai. This resetting step increases the treatment effect of the
augmented data to 0.122, matching that of the original data.
Step 3: Calibrate relative efficiency between the adjusted estimator and the unadjusted
estimator. For a∈{0,1}, we empirically estimate the marginal distribution pY ;a =P (Y =
1 |A= a) using the corresponding sample proportions in the original data. Then, for each
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participant in the n participants whose “hypothetical twin indicator” is true, with probability
0.164 we reset Yi by a realization of an independent Bernoulli random draw with success
probability pY ;Ai . This resetting step adds random noise to reduce the prognostic value in
W and L, so that the relative efficiency between the adjusted estimator and the unadjusted
estimator for the simulated data is comparable to the estimated ARE from the original
MISTIE-II dataset.
We then make modifications that are described next to assess validity of the theory
under various settings. We define eight data generating distributions, called “settings”, each
based on modifying the aforementioned data generating process. The goal is to consider
four situations involving W and/or L being prognostic or not for Y ; these are denoted by
prognW,L (both prognostic), prognW (only W prognostic), prognL (only L prognostic), and
progn∅ (neither prognostic). For each of these four situations, we consider the following two
average treatment effects: ∆ = 0 (no effect) or ∆ = 0.122 (benefit).
We first describe how we generated simulated trials with ∆ = 0.122. The aforementioned
data generating algorithm corresponds to prognW,L. To create data generating distributions
with prognW , we first generate each participant’s data as in prognW,L and then replace L
by an independent draw from the marginal distribution in the MISTIE-II data. Similarly,
in order to make only L prognostic for Y (prognL), we first generate each participant’s data
as in prognW,L and then replace W by an independent draw from the marginal distribution
in the MISTIE-II data. Lastly, to make neither W nor L prognostic, we first generate each
participant’s data as in prognW,L and then replace each of W and L by independent draws
from the corresponding marginal distributions in the MISTIE-II data, respectively.
To generate participants under ∆ = 0, the data generating process above is followed,
and then each study arm assignment A is replaced by an independent Bernoulli draw with
probability 1/2. Under the data generating process with ∆ = 0.122, there is slight treatment
effect heterogeneity γ≈ 0.01. By construction, under ∆ = 0 there is no treatment effect
heterogeneity (γ= 0).
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D Intuition for Impact of Treatment Effect Hetero-
geneity on Precision Gains
To give intuition for the phenomena in Figure 1 in Section 3.2, for the remainder of this
appendix we fix R2W and consider the simple case of a single, binary-valued W representing
being less than 65 years old at baseline, and primary outcome Y being the indicator of
having mRS at most 3 (a good outcome) at 180 days. We focus on the stratum W = 1
and assume that the under 65 subset of the study population would have better outcomes
on average than the overall study population if all were assigned to the control arm, i.e.,
E(Y |A= 0,W = 1)−E(Y |A= 0)> 0. We next consider py = 1 and the extreme of maximum
treatment effect heterogeneity (where there are no efficiency gains from adjusting for W ).
(The opposite extreme of py = 1 and no treatment effect heterogeneity is discussed in detail
in Section 3.2.)
Consider py = 1 and with maximum treatment effect heterogeneity (γ= 2R
2
W ), which
occurs when E(Y |A= 1,W )+E(Y |A= 0,W ) equals the constant E(Y |A= 1)+E(Y |A= 0).
It follows from the assumption above that those under 65 have better outcomes on average
than the overall study population in the control arm (E(Y |A= 0,W = 1)−E(Y |A= 0)> 0),
that those under 65 have worse outcomes on average than the overall study population under
assignment to the treatment arm (and by precisely the same magnitude), which follows since
E(Y |A= 1,W = 1)−E(Y |A= 1) =−{E(Y |A= 0,W = 1)−E(Y |A= 0)}. If by chance there
are proportionally more under 65 participants assigned to the treatment arm than the control
arm, then the unadjusted estimator of the mean outcome in each arm is biased downward,
and by the same amount, conditional on the chance imbalance. Since this bias cancels out
when estimating ∆, an efficient estimator of ∆ makes no adjustment. Alternatively, if by
chance there are proportionally fewer under 65 participants assigned to the treatment arm,
then by a symmetric argument an efficient estimator of ∆ makes no adjustment. The overall
impact is no adjustment due to chance imbalances in the stratum W = 1, which means
that no improvement in variance is made compared to the unadjusted estimator. This is,
intuitively, why there is no efficiency gain under maximum treatment effect heterogeneity
(γ= 2R2W ) when there are no pipeline participants (py = 1).
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We next give intuition for why one needs γ > 0 in order for pipeline participants to con-
tribute useful information toward estimating ∆ (when py < 1). Consider the case where
those in stratum W = 1 benefit more than the overall population, i.e., E(Y |A= 1,W =
1)−E(Y |A= 0,W = 1)>∆; this is only possible if γ > 0. Assume that adjustment for
chance imbalance in the stratum W = 1 between arms has already been done to the un-
adjusted estimator (using only those with Y observed), as described above. Consider the
proportion of participants having W = 1 among all participants and also among the subset
of participants with Y observed. If the former proportion is larger than the latter, then the
stratum W = 1 (of participants who benefit more than average) is underrepresented among
those with outcomes observed. An efficient estimator adjusts the estimate of ∆ upward to
compensate. Alternatively, if the former proportion is smaller than the latter, by a sym-
metric argument an efficient estimator adjusts the estimate of ∆ downward. In this way,
variance due to imbalance in the proportion with W = 1 between the overall sample (in-
cluding pipeline participants) and those with Y observed is removed. The only cases where
adjusting for the aforementioned imbalance at each level of W has no impact are when
E(Y |A= 1,W )−E(Y |A= 0,W ) = ∆, i.e., zero treatment effect heterogeneity, or py = 1 (no
pipeline participants).
E Additional Results: When Baseline Variable is Purely
Predictive or Purely Prognostic.
The following theorem examines the impact of treatment effect heterogeneity on precision
gain from adjusting for prognostic baseline variables under two extreme cases. Define
ARE(efficient,unadjusted) to be the asymptotic relative efficiency in (6). More generally,
ARE(∆̂1,∆̂2) denotes the asymptotic relative efficiency of the estimators ∆̂1,∆̂2.
Corollary 1. Suppose Assumptions 1, 2, and 3 hold. In addition, assume R2L|W = 0. For the
estimand E(Y |A= 1)−E(Y |A= 0), we have the following result regarding the asymptotic
relative efficiency between an efficient RAL estimator and the unadjusted estimator.
(i) (Maximal treatment effect heterogeneity.)
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If Var{E1(Y |W )−E0(Y |W )}> 0 and Var{E(Y |W )}= 0, then γ= 2R2W and
ARE(efficient,unadjusted) =
1
1−(1−py)R2W
. (E.1)
(ii) (No treatment effect heterogeneity.)
If Var{E1(Y |W )−E0(Y |W )}= 0 and Var{E(Y |W )}> 0, then γ= 0 and
ARE(efficient,unadjusted) =
1
1−R2W
. (E.2)
We call a baseline variable W purely predictive if it satisfies the conditions in Corollary
1(i), as it predicts the conditional average treatment effect (i.e., it identifies which strata
of W benefit from the treatment on average), but it does not explain the variance in Y
marginally (i.e., margining out A). For such a baseline variable, ARE = 1 in (E.1) when
py = 1. This means that adjusting for a purely predictive baseline variable results in no
precision gain when there are no missing primary outcomes. An extreme case of this, for
illustration only, is the following data generating distribution where the baseline variable
is perfectly correlated with the outcome within each arm but still contributes nothing to
the precision gain: W,A are independently distributed as Bernoulli(0.5) and Y =1(A=W ),
where 1(·) is the indicator function. In this case it is straightforward to verify that R2W = 1,
but adjusting for W would not impact asymptotic variance compared to the unadjusted
estimator if all participants have Y observed (py = 1) since γ= 2. Though we don’t expect
to encounter a purely predictive variable in practice, the above thought experiment shows
how W could explain treatment effect heterogeneity (which is useful on its own) while being
useless for improving precision in estimating the average treatment effect.
We call a baseline variable W purely prognostic if it satisfies the conditions in Corollary
1(ii), as the treatment effect is constant across strata of W , and W explains some of the
marginal variance in Y . For such a baseline variable, the ARE in (E.2) does not depend on
py. An intuition for why this holds, as discussed in Section 3.2, is that adjusting for such a
baseline variable reduces variance by correcting for chance imbalances between arms among
those who have Y observed, while the baseline variables for the pipeline participants contain
no information about ∆ since γ= 0 (and we are ignoring L here).
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F Precision Gain When Estimating the Treatment Spe-
cific Mean E(Y |A= a)
In this section we focus on estimating the population mean outcome under assignment to a
single arm (called the treatment specific mean): E(Y |A= a) for each a∈{0,1} separately.
The following theorem gives the lower bound on the asymptotic variance for all regular
asymptotically linear (RAL) estimators of E(Y |A= a).
Theorem F.1. Denote by pa =P (A= a) for a∈{0,1}. Assume py > 0 and 0<pa< 1. Under
Assumptions 1, 2, and 3 (except allowing pa 6= 1/2) the semiparametric lower bound on the
asymptotic variance of all RAL estimators for E(Y |A= a) is
Vara{Ea(Y |W )}+ 1
papl
Vara{Ea(Y |L,W )−Ea(Y |W )}+ 1
papy
Vara{Y −Ea(Y |L,W )}.
(F.1)
Analogous to the R-squared quantities defined in Section 3, we define new R-squared
quantities relevant to estimating the population mean of the primary outcome Y in each arm
separately. For each a∈{0,1}, define the proportion of variance in Y explained by W in arm
a as R2W ;a = Var{Ea(Y |W )}/Vara(Y ); the proportion of additional variance in Y explained
by L after accounting for W in arm a as R2L|W ;a = Vara{Ea(Y |L,W )−Ea(Y |W )}/Vara(Y ).
We also will refer to the proportion of variance in Y explained by L alone in arm a, defined
as R2L;a = Vara{Ea(Y |L)}/Vara(Y ).
The following result gives the ARE between an efficient RAL estimator and the unad-
justed estimator for E(Y |A= a).
Theorem F.2. Assume all conditions in Theorem F.1 hold. For each arm a∈{0,1}, the
asymptotic relative efficiency between an efficient RAL estimator and the unadjusted esti-
mator of the treatment specific mean E(Y |A= a) is
1
1−(1−papy)R2W ;a−(1−py/pl)R2L|W ;a
. (F.2)
When only W is prognostic (R2L|W ;a = 0), the asymptotic relative efficiency between an
efficient RAL estimator and the unadjusted estimator is equal to when the L variable is not
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Figure F.1: Asymptotic relative efficiency between an efficient RAL estimator and the un-
adjusted estimator for estimating E(Y |A= a). Plot (a) is when only the baseline variable
W is prognostic; plot (b) is when only the short-term outcome L is prognostic.
(a) (b)
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available to the efficient RAL estimator (i.e., when the efficient RAL estimator adjusts for
W alone). Similarly, when only L is prognostic (R2W ;a = 0), the asymptotic relative efficiency
is equal to when the W variable is not available to the efficient RAL estimator (i.e., when
only adjusts for L alone). In Figure F.1a we illustrate the implication of Theorem F.2 under
those special cases. We plot ARE against py when only W is prognostic (R
2
L|W ;a = 0), and in
Figure F.1b we plot ARE against py/pl when only L is prognostic (R
2
W ;a = 0). In each plot,
we separately consider prognostic value being 0.1 and 0.25. We consider three implications
of the curves in Figure F.1. First, the precision gain (ARE) from adjusting for a prognostic
baseline variable increases with a greater proportion of pipeline participants (i.e., smaller py).
The reason is that each additional pipeline participant (who has observed baseline variables
but missing outcome) contributes some information to the adjusted estimator (through the
baseline variables) but no information to the unadjusted estimator. For a similar reason, the
precision gain from adjusting for a prognostic short-term outcome increases with a greater
proportion of participants with W,L but not Y observed (i.e., smaller py/pl).
Second, when every participant has their primary outcome observed (e.g., at the final
analysis time of a group sequential design with no dropouts), adjusting for the prognostic
baseline variables still improves estimation precision as long as R2W ;a> 0, but adjusting for
prognostic short-term outcome no longer does.
Third, for any given (py,pl), adjusting for a prognostic baseline variable alone always
leads to larger precision gain than adjusting for an equally prognostic short-term outcome
alone.
Following the discussion in Section A, we define the asymptotic equivalent reduction in
sample size (AERSS) of ∆̂1 compared to ∆̂2 as
AERSS(∆̂1,∆̂2) = 1−ARE(∆̂1,∆̂2)−1. (F.3)
Adjusting for prognostic W alone with R2W ;a = q (for 0<q< 1) yields AERSS = q(1−py/2),
and adjusting for prognostic L alone with R2L;a = q yields AERSS = q(1−py/pl). The ratio
of the two AERSSs equals (assuming q > 0)
r=
AERSS from adjusting only for prognostic W with R2W ;a = q
AERSS from adjusting only for prognostic L with R2L;a = q
=
1−py/2
1−py/pl . (F.4)
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r > 1 means that the sample size reduction from adjusting for a prognostic W is larger than
that from adjusting for an equally prognostic L; r < 1 means the opposite. Figure F.2 plots
r against (pl,py) under the constraint 0<py≤ pl≤ 1. For all such (pl,py), r > 1. In addition,
we have r≥ 2 if py≥ 2/3. This means that if at most 1/3 of the enrollees are in the pipeline,
the sample size reduction from adjusting for a prognostic short-term outcome alone is at
most half of that from adjusting for an equally prognostic baseline variable alone. Roughly
speaking, small py makes r close to 1, meaning that adjusting for W or adjusting for L results
in a similar sample size reduction when there are relatively few with Y observed. This may
occur at early stages of a group sequential design, if the delay of the primary outcome is
long relative to the enrollment rate.
Figure F.2: Contour plot of r(pl,py), where r is the ratio of the reductions in sample size
when only W is prognostic with R2W ;a = q and when only L is prognostic with R
2
L;a = q, for
any fixed q ∈ (0,1). The estimand is the treatment specific mean E(Y |A= a).
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G Simulation Results for Relative Efficiency When Es-
timating the Treatment Specific Mean
The simulation setup, including the data generating distributions (settings), are the same as
Section 6. Table G.1 gives the values of R2W ;a and R
2
L|W ;a for a∈{0,1}, which are defined in
the paragraph after Theorem F.1. Tables G.2 and G.3 list the asymptotic relative efficiency
(ARE) approximated by substituting model-based estimates of the conditional expectations
in the quantities in (F.2).
Table G.1: R2W ;a and R
2
L|W ;a for a∈{0,1} for the data generating distributions from the
settings in Section 6, approximated based on a simulated dataset with 1,000,000 participants
under each setting.
prognW,L prognW prognL progn∅
∆ = 0 ∆ = 0.122 ∆ = 0 ∆ = 0.122 ∆ = 0 ∆ = 0.122 ∆ = 0 ∆ = 0.122
R2W ;0 0.35 0.33 0.35 0.33 0 0 0 0
R2L|W ;0 0.08 0.06 0 0 0.30 0.28 0 0
R2W ;1 0.35 0.38 0.35 0.38 0 0 0 0
R2L|W ;1 0.08 0.08 0 0 0.30 0.31 0 0
H Proofs
We prove the results in the main paper as well as results in Section E and Section F. Auxiliary
lemmas (used in these proofs) are proved Section I.
H.1 Identification of the average treatment effect
Under Assumptions 1-3, the average treatment effect can be expressed as follows:
E(Y |A= 1)−E(Y |A= 0) = E[E{E(Y |L,W,A= 1,CY = 1) |W,CL = 1,A= 1}]
−E[E{E(Y |L,W,A= 0,CY = 1) |W,CL = 1,A= 0}] (H.1)
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Table G.2: Comparison of the asymptotic relative efficiency (ARE) predicted by Theorem
F.2 and the relative efficiency computed from simulated trials under ∆ = 0. The maximum
sample size nmax is set to be 300 under prognW,L and prognW , and is set to 480 under prognL
and progn∅. Under each setting the same nmax is used for both the unadjusted estimator
and the adjusted estimator. The simulated RE is based on 50,000 simulated trials.
Under ∆ = 0 ARE from theory RE from Simulation
prognW,L prognW prognL progn∅ prognW,L prognW prognL progn∅
Estimand: E(Y |A= 0)
Interim
Analysis
1 1.44 1.36 1.13 1.00 1.34 1.29 1.09 0.97
2 1.35 1.31 1.07 1.00 1.32 1.28 1.06 0.99
3 1.32 1.29 1.05 1.00 1.29 1.27 1.04 0.99
4 1.29 1.26 1.04 1.00 1.27 1.25 1.03 0.99
Decision
Analysis
1 1.21 1.21 1.00 1.00 1.19 1.20 0.99 0.99
2 1.21 1.21 1.00 1.00 1.19 1.20 0.99 0.99
3 1.21 1.21 1.00 1.00 1.20 1.20 0.99 0.99
4 1.21 1.21 1.00 1.00 1.20 1.21 1.00 1.00
5 1.21 1.21 1.00 1.00 1.20 1.21 1.00 1.00
Estimand: E(Y |A= 1)
Interim
Analysis
1 1.44 1.37 1.13 1.00 1.34 1.28 1.10 0.97
2 1.36 1.31 1.07 1.00 1.33 1.29 1.06 0.99
3 1.32 1.29 1.05 1.00 1.31 1.27 1.04 0.99
4 1.29 1.26 1.04 1.00 1.28 1.26 1.03 0.99
Decision
Analysis
1 1.21 1.21 1.00 1.00 1.20 1.20 0.99 0.99
2 1.21 1.21 1.00 1.00 1.20 1.21 0.99 0.99
3 1.21 1.21 1.00 1.00 1.20 1.21 0.99 0.99
4 1.21 1.21 1.00 1.00 1.21 1.21 1.00 1.00
5 1.21 1.21 1.00 1.00 1.21 1.21 1.00 1.00
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Table G.3: Comparison of the asymptotic relative efficiency (ARE) predicted by Theorem F.2
and the relative efficiency computed from simulated trials under ∆ = 0.122. The maximum
sample size nmax is set to be 300 under prognW,L and prognW , and is set to 480 under prognL
and progn∅. Under each setting the same nmax is used for both the unadjusted estimator
and the adjusted estimator. The simulated RE is based on 50,000 simulated trials.
Under ∆ = 0.122 RE approximated by Theory RE from Simulation
prognW,L prognW prognL progn∅ prognW,L prognW prognL progn∅
Estimand: E(Y |A= 0)
Interim
Analysis
1 1.59 1.54 1.14 1.00 1.49 1.43 1.10 0.97
2 1.48 1.45 1.08 1.00 1.46 1.41 1.07 0.99
3 1.43 1.41 1.06 1.00 1.44 1.40 1.05 0.99
4 1.39 1.38 1.04 1.00 1.40 1.38 1.03 0.99
Decision
Analysis
1 1.30 1.30 1.00 1.00 1.28 1.28 0.99 0.99
2 1.30 1.30 1.00 1.00 1.29 1.29 0.99 0.99
3 1.30 1.30 1.00 1.00 1.30 1.30 0.99 0.99
4 1.30 1.30 1.00 1.00 1.30 1.30 1.00 1.00
5 1.30 1.30 1.00 1.00 1.30 1.30 1.00 1.00
Estimand: E(Y |A= 1)
Interim
Analysis
1 1.37 1.30 1.11 1.00 1.26 1.21 1.08 0.97
2 1.30 1.26 1.07 1.00 1.26 1.22 1.05 0.99
3 1.27 1.24 1.05 1.00 1.24 1.21 1.04 0.99
4 1.24 1.22 1.04 1.00 1.23 1.19 1.03 0.99
Decision
Analysis
1 1.18 1.18 1.00 1.00 1.16 1.16 0.99 0.99
2 1.18 1.18 1.00 1.00 1.16 1.16 0.99 0.99
3 1.18 1.18 1.00 1.00 1.17 1.16 0.99 0.99
4 1.18 1.18 1.00 1.00 1.17 1.16 1.00 1.00
5 1.18 1.18 1.00 1.00 1.17 1.16 1.00 1.00
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The proof of (H.1) is given as follows.
Proof. It suffices to show that for each a∈{0,1} the following holds:
E(Y |A= a) =E[E{E(Y |L,W,A= a,CY = 1) |W,A= a,CL = 1}]. (H.2)
Using the law of iterated expectation twice, we deduce
E(Y |A= a) =E[E{E(Y |L,W,A= a) |W,A= a}]. (H.3)
Let f(L,W ) =E(Y |L,W,A= a). By Assumption 2 we have
E(f(L,W ) |A= a) =E(f(L,W ) |A= a,CL = 1), (H.4)
and
E(Y |L,W,A= a) =E(Y |L,W,A= a,CL = 1,CY = 1). (H.5)
Equations (H.3)-(H.5) together yield
E(Y |A= a) =E[E{E(Y |L,W,A= a,CL = 1,CY = 1) |W,A= a,CL = 1}]. (H.6)
Equation (H.6) and Assumption 3 yield (H.2). This completes the proof.
H.2 Lemma on Variance Decomposition
Lemma H.1. For study arm a∈{0,1}, we have the following decomposition of the variance
of Y in that arm:
Vara(Y ) = Vara{Ea(Y |W )}+Vara{Ea(Y |L,W )−Ea(Y |W )}+Vara{Y −Ea(Y |L,W )}.
(H.7)
In addition, we have
R2W ;a+R
2
L|W ;a+R
2
r;a = 1, for each a∈{0,1}. (H.8)
Proof. Adding and subtracting terms, we have
Vara(Y ) = Vara
[{Y −Ea(Y |L,W )}+{Ea(Y |L,W )−Ea(Y |W )}+Ea(Y |W )]. (H.9)
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So for proving (H.7), it suffices to establish the following:
Cova
{
Y −Ea(Y |L,W ),Ea(Y |L,W )−Ea(Y |W )
}
= 0, (H.10)
Cova
{
Y −Ea(Y |L,W ),Ea(Y |W )
}
= 0, (H.11)
Cova
{
Ea(Y |L,W )−Ea(Y |W ),Ea(Y |W )
}
= 0, (H.12)
where Cova denotes the conditional covariance given A= a.
First, we have
Cova
{
Y −Ea(Y |L,W ),Ea(Y |L,W )−Ea(Y |W )
}
=Ea
{
Y Ea(Y |L,W )−Ea(Y |L,W )2−Y Ea(Y |W )+Ea(Y |L,W )Ea(Y |W )
}
. (H.13)
By Lemma I.1 with X =Z = (L,W ), we have
Ea
{
Y Ea(Y |L,W )
}
=Ea
{
Ea(Y |L,W )2
}
. (H.14)
By Lemma I.1 with X =W and Z = (L,W ), we have
Ea
{
Y Ea(Y |W )
}
=Ea
{
Ea(Y |L,W )Ea(Y |W )
}
. (H.15)
Equations (H.13), (H.14), and (H.15) imply (H.10).
Second, we have
Cova
{
Y −Ea(Y |L,W ),Ea(Y |W )
}
=Ea
{
Y Ea(Y |W )−Ea(Y |L,W )Ea(Y |W )
}
. (H.16)
Equations (H.16) and (H.15) imply (H.11).
Third, since Ea(Y |L,W )−Ea(Y |W ) has expectation zero, we have
Cova
{
Ea(Y |L,W )−Ea(Y |W ),Ea(Y |W )
}
=Ea
{
Ea(Y |L,W )Ea(Y |W )−Ea(Y |W )2
}
.
(H.17)
In Lemma I.1, letting X =Z =W and replacing Y in the lemma by E(Y |L,W ) implies
Ea
{
Ea(Y |L,W )Ea(Y |W )
}
=Ea
{
Ea(Y |W )2
}
. (H.18)
Equations (H.17) and (H.18) imply (H.12).
This proves (H.7). Equation (H.8) follows immediately from (H.7) and the definition of
R2W ;a, R
2
L|W ;a and R
2
r;a. This completes the proof for Lemma H.1.
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H.3 Proof of Theorem F.1
Proof. In the proof, we will use equation (H.6) derived earlier; we rewrite it below:
E(Y |A= a) =E[E{E(Y |L,W,A= a,CL = 1,CY = 1) |W,A= a,CL = 1}]. (H.19)
Treating the missingness indicators CL and CY as binary treatments, the right-hand side
of (H.19) becomes the average of outcome Y under time dependent treatment assignment:
A= a,CL = 1,CY = 1. Because there is no measurement made between A and CL, we can
combine the two as a single treatment A˜, with A˜= 1 if and only if A= a and CL = 1. Equation
(H.19) becomes
E(Y |A= a) =E[E{E(Y |L,W,A˜= 1,CY = 1) |W,A˜= 1}]. (H.20)
Using the fact that L is binary-valued, by equations (24) and (28) in Rosenblum and van der
Laan (2011) or Theorem 1 in van der Laan (2010), the efficient influence function for (H.20)
is
D(W,A˜,L,CY ,Y ) =D0(W )+D1(W,A˜,L)+D2(W,A˜,L,C
Y ,Y ), (H.21)
where
D0(W ) =E(Y |W,A˜= 1,CY = 1)−E(Y | A˜= 1), (H.22)
D1(W,A˜,L) =
1(A˜= 1)
{
E(Y |L,W,A˜= 1,CY = 1)−E(Y |W,A˜= 1,CY = 1)}
P (A˜= 1 |W ) , (H.23)
and
D2(W,A˜,L,C
Y ,Y ) =
1(CY = 1)1(A˜= 1)
{
Y −E(Y |L,W,A˜= 1,CY = 1)}
P (CY = 1 |L,W,A˜= 1)P (A˜= 1 |W ) . (H.24)
By randomization and independent censoring assumptions, (H.22) simplifies to
D0(W ) =E(Y |W,A= a)−E(Y |A= a); (H.25)
equation (H.23) simplifies to
D1(W,A˜,L) =
1(A˜= 1)
{
E(Y |L,W,A= a)−E(Y |W,A= a)}
P (A˜= 1)
; (H.26)
equation (H.24) simplifies to
D2(W,A˜,L,C
Y ,Y ) =
1(CY = 1)1(A˜= 1)
{
Y −E(Y |L,W,A= a)}
P (CY = 1 |CL = 1)P (A˜= 1) . (H.27)
The following lemma states that D0, D1, and D2 are pairwise uncorrelated.
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Lemma H.2. We have
Cov{D0(W ),D1(W,A˜,L)}= 0, (H.28)
Cov{D0(W ),D2(W,A˜,L,CY ,Y )}= 0, (H.29)
Cov{D1(W,A˜,L),D2(W,A˜,L,CY ,Y )}= 0. (H.30)
Lemma H.2 implies
Var{D(W,A˜,L,CY ,Y )}= Var{D0(W )}+Var{D1(W,A˜,L)}+Var{D2(W,A˜,L,CY ,Y )}.
(H.31)
By (H.25) we have
Var{D0(W )}= Var{Ea(Y |W )}= Vara{Ea(Y |W )}, (H.32)
where the last equality follows from randomization assumption. By (H.26) we haveE{D1(W,A˜,L)}=
0, so it follows from randomization and independent censoring that
Var{D1(W,A˜,L)}=E
[1(A˜= 1)2{E(Y |L,W,A= a)−E(Y |W,A= a)}2
P (A˜= 1)2
]
=
E{1(A˜= 1)}
P (A˜= 1)2
E
[{
E(Y |L,W,A= a)−E(Y |W,A= a)}2 |A= a].
(H.33)
By independent censoring we have P (A˜= 1) = papl. It then follows from (H.33) and random-
ization assumption that
Var{D1(W,A˜,L)}= 1
papl
Vara
{
Ea(Y |L,W )−Ea(Y |W )
}
. (H.34)
Similarly, (H.27) together with randomization and monotone censoring imply
Var{D2(W,A˜,L,CY ,Y )}= 1
papy
Vara
{
Y −Ea(Y |L,W )
}
. (H.35)
Because the semiparametric lower bound on the asymptotic variance for an estimand
equals the variance of the efficient influence function, by (H.31), (H.32), (H.34), and (H.35)
we proved (F.1).
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H.4 Proof of Theorem F.2
Proof. The unadjusted estimator τ̂ for E(Y |A= a) is defined as
τ̂ =
∑n
i=1Yi1(Ai = a,C
Y
i = 1)∑n
i=11(Ai = a,C
Y
i = 1)
. (H.36)
Under Assumptions 1 and 2, τ̂ is unbiased:
E(τ̂) =E
[
E
{∑n
i=1Yi1(Ai = a,C
Y
i = 1)∑n
i=11(Ai = a,C
Y
i = 1)
∣∣∣A1,...,An,CY1 ,...,CYn}]=E(Y |A= a). (H.37)
In the following we calculate the asymptotic variance of τ̂ .
√
n{τ̂−E(Y |A= a)}=
1√
n
∑n
i=1Yi1(Ai = a,C
Y
i = 1)
1
n
∑n
i=11(Ai = a,C
Y
i = 1)
−√nE(Y |A= a)
=
1√
n
∑n
i=1{Yi−E(Y |A= a)}1(Ai = a,CYi = 1)
1
n
∑n
i=11(Ai = a,C
Y
i = 1)
. (H.38)
By Weak Law of Large Numbers and the independent censoring assumption,
1
n
n∑
i=1
1(Ai = a,C
Y
i = 1)
P→ papy, (H.39)
where
P→ denotes convergence in probability. By Central Limit Theorem,
1√
n
n∑
i=1
{Yi−E(Y |A= a)}1(Ai = a,CYi = 1) d→N(0,σ2), (H.40)
where by randomization and independent censoring we have
σ2 = Var
[{Y −E(Y |A= a)}1(A= a,CY = 1)]=E[{Y −E(Y |A= a)}21(A= a,CY = 1)2]
= papyVar(Y |A= a). (H.41)
Combining (H.38)-(H.41), it follows from Slutsky’s theorem that
√
n{τ̂−E(Y |A= a)} d→N(0,(papy)−1Var(Y |A= a)).
So the asymptotic variance of τ̂ is (papy)
−1Var(Y |A= a), which by randomization yields
(recall that by definition Vara(Y ) = Var(Y |A= a))
AVar(unadjusted) =
1
papy
Vara(Y ). (H.42)
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Equations (H.42) and (H.8) imply
AVar(unadjusted) =
1
papy
Vara(Y )(R
2
W ;a+R
2
L|W ;a+R
2
r;a). (H.43)
On the other hand, Theorem F.1 and the definition of R2W and R
2
r imply
AVar(efficient) = Vara(Y )(R
2
W ;a+
1
papl
R2L|W ;a+
1
papy
R2r;a). (H.44)
Equations (H.43), (H.44), and (H.8) yield (F.2). The proof is thus finished.
H.5 Generalization and proof of Lemma 1
We provide proof for a generalization of Lemma 1, which allows for constant randomization
probability other than 1/2.
Lemma H.3. Suppose Assumptions 1, 2, and 3 hold. Define P (A= a) = pa for a∈{0,1}.
The lower bound on the asymptotic variance of all RAL estimators of E(Y |A= 1)−E(Y |
A= 0) is
Var{E1(Y |W )−E0(Y |W )}+
∑
a∈{0,1}
1
papl
Vara{Ea(Y |L,W )−Ea(Y |W )}
+
∑
a∈{0,1}
1
papy
Vara{Y −Ea(Y |L,W )}. (H.45)
Proof. For notation simplicity, denote by Q(·) the conditional expectation E(Y | ·). Using the
derivation in (H.19)-(H.27) twice for A= 1 and A= 0, we get the efficient influence function
D(W,A,CL,L,CY ,Y ) for E(Y |A= 1)−E(Y |A= 0):
D(W,A,CL,L,CY ,Y ) =D0(W )+D1(W,A,C
L,L)+D2(W,A,C
L,L,CY ,Y ), (H.46)
where
D0(W ) =
{
Q(W,A= 1)−Q(A= 1)}−{Q(W,A= 0)−Q(A= 0)}, (H.47)
D1(W,A,C
L,L) =
ACL
p1pl
{
Q(W,L,A= 1)−Q(W,A= 1)}
− (1−A)C
L
p0pl
{
Q(W,L,A= 0)−Q(W,A= 0)}, (H.48)
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and
D2(W,A,C
L,L,CY ,Y ) =
ACY
p1py
{
Y −Q(W,L,A= 1)}− (1−A)CY
p0py
{
Y −Q(W,L,A= 0)}.
(H.49)
The following lemma states that D0, D1, and D2 are pairwise uncorrelated.
Lemma H.4. We have
Cov{D0(W ),D1(W,A,CL,L)}= 0, (H.50)
Cov{D0(W ),D2(W,A,CL,L,CY ,Y )}= 0, (H.51)
Cov{D1(W,A,CL,L),D2(W,A,CL,L,CY ,Y )}= 0. (H.52)
Lemma H.4 implies
Var{D(W,A,CL,L,CY ,Y )}=Var{D0(W )}+Var{D1(W,A,CL,L)}
+Var{D2(W,A,CL,L,CY ,Y )}. (H.53)
By H.47 we have
Var{D0(W )}= Var{Q(W,A= 1)−Q(W,A= 0)}. (H.54)
By (H.48) we have
Var{D1(W,A,CL,L)}=E
[ACL
p21p
2
l
{
Q(W,L,A= 1)−Q(W,A= 1)}2]
+E
[(1−A)CL
p20p
2
l
{
Q(W,L,A= 0)−Q(W,A= 0)}2] (H.55)
=
∑
a∈{0,1}
1
papl
E
[{
Q(W,L,A= a)−Q(W,A= a)}2 |A= a] (H.56)
=
∑
a∈{0,1}
1
papl
Var
{
Q(W,L,A= a)−Q(W,A= a) |A= a}. (H.57)
The step from (H.55) to (H.56) utilizes the independent censoring and randomization as-
sumptions. Similarly, (H.49) together with randomization and independent censoring imply
Var{D2(W,A,CL,L,CY ,Y )}=
∑
a∈{0,1}
1
papl
Var
{
Y −Q(W,L,A= a) |A= a}. (H.58)
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Because the semiparametric lower bound on the asymptotic variance for an estimand
equals the variance of the efficient influence function, by (H.53), (H.54), (H.57), and (H.58)
we proved Lemma 1.
H.6 Proof of Theorem 2
Proof. The unadjusted estimator for the average treatment effect is
τ̂ =
∑n
i=1Yi1(Ai = 1,C
Y
i = 1)∑n
i=11(Ai = 1,C
Y
i = 1)
−
∑n
i=1Yi1(Ai = 0,C
Y
i = 1)∑n
i=11(Ai = 0,C
Y
i = 1)
.
Similar to the derivation from (H.36) to (H.42), when estimating the average treatment effect
with P (A= 1) =P (A= 0) = 1/2, we have
AVar(unadjusted) =
2
py
∑
a∈{0,1}
Vara(Y ). (H.59)
The result in Theorem 2 then follows immediately from Lemma 1.
H.7 Proof of Corollary 1
Proof. (i) Because
Var{E(Y |W )}= Var{0.5E(Y |W,A= 1)+0.5E(Y |W,A= 1)},
Var{E(Y |W )}= 0 implies
Var{E(Y |W,A= 1)}+Var{E(Y |W,A= 0)}=−2Cov{E(Y |W,A= 1),E(Y |W,A= 0).
(H.60)
By (H.60) and the definition of γ and R2W , we have γ= 2R
2
W . This combined with (6)
with R2L|W = 0 imply (E.1).
(ii) By the definition of γ and Var{E(Y |W,A= 1)−E(Y |W,A= 0)}= 0, (E.2) follows
immediately from (6) with R2L|W = 0.
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H.8 Proof of statements in Section 3.4
For ease of reading we restate the claims to be proven in Section 3.4: We compare the
ARE between two cases: R2W = q > 0,R
2
L|W = 0 (only baseline variable prognostic) and R
2
W =
0,R2L|W = q > 0 (only short-term outcome prognostic). Regardless of the value of q > 0, the
ARE in the former case is larger or equal to that in the latter case. Equality occurs if and
only if pl = 1 and W is uncorrelated with Y (marginally) in the former case. The latter
condition is equivalent to the treatment effect heterogeneity being the maximum possible
γ= 2R2W = 2q.
Proof. We first show that γ≤ 2R2W with equality holds only when E1(Y |W ) =−E0(Y |W )
almost surely. By Cauchy-Schwarz inequality we have
Var{E1(Y |W )−E0(Y |W )}
= Var{E1(Y |W )}+Var{E0(Y |W )}−2Cov{E1(Y |W ),E0(Y |W )}
≤Var{E1(Y |W )}+Var{E0(Y |W )}+2[Var{E1(Y |W )}Var{E0(Y |W )}]1/2
≤ 2Var{E1(Y |W )}+2Var{E0(Y |W )},
where both inequalities becomes equality if and only if E1(Y |W ) =−E0(Y |W ) almost
surely. This proves the claim.
Theorem 2 states that the ARE equals (where we indicate dependence on the arguments
by explicitly writing them out)
ARE(R2W ,R
2
L|W ,γ,py,pl) =
1
1+(py/2)γ−R2W −(1−py/pl)R2L|W
.
When R2W = q > 0,R
2
L|W = 0,
ARE(q,0,γ,py,pl) =
1
1+(py/2)γ−q ≥
1
1−(1−py)q ,
with equality holds if and only if γ= 2q. When R2W = 0,R
2
L|W = q > 0 (which implies γ= 0
because γ≤ 2R2W ),
ARE(0,R2L|W ,0,py,pl) =
1
1−(1−py/pl)q .
Because pl≤ 1, ARE(q,0,γ,py,pl)≥ARE(0,R2L|W ,0,py,pl) with equality holds if and only if
pl = 1 and γ= 2q, i.e., E1(Y |W ) =−E0(Y |W ) almost surely.
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Lastly, we show that E1(Y |W ) =−E0(Y |W ) almost surely implies that W is uncorre-
lated with Y (marginally):
Cov(Y,W ) =E{Y (W −E(W ))}=E{E(Y |W )(W −E(W ))}
=E{E(Y |W )(W −E(W ))}=E [{0.5E1(Y |W )+0.5E0(Y |W )}(W −E(W ))] = 0.
This completes the proof.
I Proof of Auxiliary Lemmas
I.1 Additional Supporting Lemmas
Lemma I.1. Consider three random variables X, Y , and Z. Denote by σ(Z) the σ-field
generated by Z. If X ∈σ(Z), then
E
{
Y E(Y |X)}=E{E(Y |Z)E(Y |X)}. (I.1)
Proof. By the law of iterated expectation, we have
E
{
Y E(Y |X)}=E[E{Y E(Y |X) |Z}]. (I.2)
Because X ∈σ(Z), we have E(Y |X)∈σ(X)⊂σ(Z). This implies
E
{
Y E(Y |X) |Z}=E(Y |X)E(Y |Z). (I.3)
Equations (I.2) and (I.3) imply (I.1). This completes the proof.
Lemma I.2. Consider three random variables W , L, and Y . For any measurable functions
f(W ) and g(W,L), we have
E
[
f(W )
{
E(Y |W,L)−E(Y |W )}]= 0, (I.4)
E
[
g(W,L)
{
Y −E(Y |W,L)}]= 0. (I.5)
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Proof. By the law of iterated expectation, we have
E
{
g(W )E(Y |W,L)}=E[E{g(W )E(Y |W,L) |W}]
=E
[
g(W )E
{
E(Y |W,L) |W}]
=E
{
g(W )E(Y |W )},
which proves (I.4).
Similarly, we have
E
{
g(W,L)Y
}
=E
[
E
{
g(W,L)Y |W,L}]=E{g(W,L)E(Y |W,L)},
which proves (I.5).
I.2 Proof of Lemma H.2
Proof. By (H.25) and (H.26) we have
Cov(D0,D1)∝E
[
1(A˜= 1){Ea(Y |W )−Ea(Y )}{Ea(Y |L,W )−Ea(Y |W )}
]
. (I.6)
Combining (H.12), (I.6), and Assumptions 1 and 2, we derive (H.28).
By (H.25) and (H.27) we have
Cov(D0,D2)∝E
[
1(A˜= 1,CY = 1){Ea(Y |W )−Ea(Y )}{Y −Ea(Y |L,W )}
]
. (I.7)
Combining (H.11), (I.7), and Assumptions 1 and 2, we derive (H.29).
By (H.26) and (H.27) we have
Cov(D1,D2)∝E
[
1(A˜= 1,CY = 1){Ea(Y |L,W )−Ea(Y |W )}{Y −Ea(Y |L,W )}
]
. (I.8)
Combining (H.10), (I.8), and Assumptions 1 and 2, we derive (H.30).
This completes the proof.
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I.3 Proof of Lemma H.4
For notation simplicity, we use E1(·) and E0(·) to denote E(· |A= 1) and E(· |A= 0), re-
spectively. By (H.47) and (H.48) we have
Cov(D0,D1)∝E
[
A
{
Q(W,A= 1)−Q(W,A= 0)}{Q(W,L,A= 1)−Q(W,A= 1)}]
−E[(1−A){Q(W,A= 1)−Q(W,A= 0)}{Q(W,L,A= 0)−Q(W,A= 0)}]
=
∑
a∈{0,1}
Ea
[{
E1(Y |W )−E0(Y |W )
}{
Ea(Y |W,L)−Ea(Y |W )
}×P (A= a).
(I.9)
Both terms in (I.9) equals 0 by (I.4) in Lemma I.2 with f(W ) =E1(Y |W )−E0(Y |W ). This
yields (H.50).
By (H.47) and (H.49) we have
Cov(D0,D2)∝E
[
A
{
Q(W,A= 1)−Q(W,A= 0)}{Y −Q(W,L,A= 1)}]
−E[(1−A){Q(W,A= 1)−Q(W,A= 0)}{Y −Q(W,L,A= 0)}]
=
∑
a∈{0,1}
Ea
[{
E1(Y |W )−E0(Y |W )
}{
Y −Ea(Y |W,L)
}×P (A= a). (I.10)
Both terms in (I.10) equals 0 by (I.5) in Lemma I.2 with g(W,L) =E1(Y |W )−E0(Y |W ).
This yields (H.51).
By (H.48) and (H.49) we have
Cov(D1,D2)∝E
[
A
{
Q(W,L,A= 1)−Q(W,A= 1)}{Y −Q(W,L,A= 1)}]
−E[(1−A){Q(W,L,A= 0)−Q(W,A= 0)}{Y −Q(W,L,A= 0)}]
=
∑
a∈{0,1}
Ea
[{
Ea(Y |W,L)−Ea(Y |W )
}{
Y −Ea(Y |W,L)
}×P (A= a).
(I.11)
Both terms in (I.11) equals 0 by (I.5) in Lemma I.2 with g(W,L) =Ea(Y |W,L)−Ea(Y |W ).
This yields (H.52).
This completes the proof.
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